Chief Investigators: Fahey, Novak, Colditz. Cell Care and CPA (2015-2019) $900k.
Aims: Determine the safety and preliminary efficacy of sibling-matched UCB infused into children with CP. Determine the feasibility and acceptability and duration of effects.
Mechanism: Anti-inflammatory and trophic.
New Knowledge: Establishing safety, feasibility and preliminary efficacy of sibling-matched UCB.